Samrat Pharmachem Ltd. Receives Credit Rating Upgrade from Crisil

Samrat Pharmachem Ltd. Receives Credit Rating Upgrade from Crisil​

Samrat Pharmachem Ltd. announced a credit rating upgrade from Crisil Limited on March 30, 2026. The rating agency has revised the bank facilities to 'Crisil BB/Stable/ Crisil A4+' from the previous rating of 'Crisil BB+/Negative/Crisil A4+'.

The upgraded rating reflects a positive assessment of the company’s financial health and operational performance. Further details regarding the rating rationale are available on the company’s website at www.samratpharmachem.com.

Source:​

Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.

The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.